Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

EGFR mutations and ALK rearrangements: Where are we now and where do we need to go to optimize treatment paradigms for our patients?

Beyond ex19del and L858R: Update on EGFRex20 insertions and other uncommon EGFR mutations

31 Mar 2023

EGFR mutations and ALK rearrangements: Where are we now and where do we need to go to optimize treatment paradigms for our patients?

Non-Small Cell Lung Cancer

Xiuning Le

X. Le

Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Centerncer Center, 77030 - Houston/US

This content is available to ESMO members and event participants.

31 Mar 2023

Presenter: Mariana Brandão

Session: EGFR mutations and ALK rearrangements: Where are we now and where do we need to go to optimize treatment paradigms for our patients?

Resources:

Slides

Webcast

31 Mar 2023

Presenter: Margarita Majem Tarruella

Session: EGFR mutations and ALK rearrangements: Where are we now and where do we need to go to optimize treatment paradigms for our patients?

Resources:

Slides

Webcast

31 Mar 2023

Presenter: Heather Wakelee

Session: EGFR mutations and ALK rearrangements: Where are we now and where do we need to go to optimize treatment paradigms for our patients?

Resources:

Webcast